This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive t…

Advanced Or Metastatic Merkel Cell Carcinoma

~Estimated

~$10 – $8,750

TuHURA Biosciences, Inc.NCT06947928

Phase 1

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed…

Solid Tumor, AdultMicrosatellite Stable Colorectal CancerHead and Neck Squamous Cell Carcinoma+10 more

~Estimated

~$10 – $8,750

KaliVir ImmunotherapeuticsNCT06444815

← PreviousPage 3 of 3Next →